CYP2C19

Across TCGA pan-cancer cohorts, CYP2C19 RNA differs between tumor and matched normal tissue in 5 of 18 cancer types tested, making tumor–normal expression one of CYP2C19’s most consistent transcriptional readouts.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where CYP2C19 RNA is repressed in tumor relative to normal tissue. In most cancer types CYP2C19 is over-expressed in tumor, although a few such as LIHC and CHOL show the opposite, repressed pattern.

LIHC, LUSC, and CHOL are the cancer types where CYP2C19 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in CYP2C19 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LIHC	Female	II,III,IV	−3.032	<.001	6	view →
LUSC	All	All	+0.037	<.001	4	view →
CHOL	All	All	−2.092	<.001	3	view →
PAAD	Female	All	+0.090	.046	2	view →
BRCA	All	All	−0.003	.008	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 5 strongest of 5 lineages.

CYP2C19–LIHC

Open the LIHC breakdown →